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The incidence of oropharyngeal 
squamous cell carcinoma (OPSCC) 
in the Western world has significantly 
increased, and only in recent times has 
human papillomavirus type 16 (HPV-16) 
been identified as the principal caus-
ative agent of this neoplasm, presently 
accounting for around 40–80% of cases.1
Although HPV+ OPSCCs often pres-
ent at advanced stage with regional lymph 
node metastasis, studies report signifi-
cantly better long-term survival for most 
HPV+ OPSCC patients compared with 
those affected by HPV- (tobacco-related) 
disease.1 The reason for this survival 
advantage is unclear, and may be multi-
factorial, perhaps linked to the retained 
expression of wild-type p53 (TP53) and 
retinoblastoma 1 (Rb1) tumor suppres-
sor genes, or the absence of field cancer-
ization.1 Of note, the improved survival 
of HPV+ OPSCC patients appears to be 
independent of treatment modality (be it 
surgery, radiotherapy, chemotherapy, or 
combinations thereof),1,2 raising the pos-
sibility that some of these patients receive 
unnecessary treatment. Based on these 
observations, various clinical trials are 
currently testing treatment de-escalation, 
in order to reduce therapy-related morbid-
ity. However, a minority of HPV+ OPSCC 
patients respond poorly to treatment and 
have a poor prognosis. It has been sug-
gested that future clinical investigations 
focus on this patient group, in order to 
improve outcome (and to avoid treat-
ment de-intensification in this setting). 
Although smoking has been shown to 
reduce the survival benefit of individu-
als with HPV+ OPSCC patients,3 there 
is as yet, no single clinical or morpho-
logical feature for identifying those HPV+ 
OPSCC patients who will have poor dis-
ease outcome.
We hypothesized that the difference in 
survival between HPV+ and HPV− patients 
is due to an adaptive immune response 
directed against the viral antigens expressed 
by tumor cells. The abundance of tumor-
infiltrating lymphocytes (TIL) has been 
shown to be a predictor of positive disease 
outcome in several tumor types, particu-
larly colorectal cancer, suggesting that the 
adaptive immune system plays a role in sup-
pressing tumor progression. Importantly, 
immune responses against foreign viral 
antigens are less likely to be suppressed 
since there is no central immunological 
tolerance to confound the immune system’s 
attempts to control cancer. We therefore 
conducted a study to examine the effects of 
HPV status and TIL levels on the survival 
of OPSCC patients using cohorts from 
independent clinical centers.
We recently reported that HPV+ 
OPSCCs are associated with significantly 
improved survival (3-y survival rate of 
combined cohorts: 79% vs. 51% for HPV+ 
and HPV− OPSCC patients, respectively; 
P < 0.001).4 We found that most (85%) 
of HPV+ tumors contain high or moder-
ate levels of TILs, and that TIL levels 
stratify HPV+ OPSCC patients into those 
with good and poor prognosis (Fig. 1). 
The 3-y survival rate (of combined 
cohorts) for patients with HPV+/TILhigh 
tumors was 94%, compared with 72% for 
HPV+/TILmod and 56% for HPV+/TILlow 
tumors. Of note, the survival of individu-
als with HPV+/TILlow tumors was similar 
to that of patients with HPV− OPSCCs 
(3-y survival rate 51%). We also quanti-
fied the densities of CD3+, CD4+, CD8+, 
and Foxp3+ T cells and performed receiver 
operating characteristic (ROC) analyses 
to determine the predictive value of the 
absolute or relative levels of these TIL 
subsets. These more complex analyses 
did not outperform the simple quantifi-
cation of TIL performed on hematoxylin 
and eosin (H+E)-stained sections. Several 
groups have reported that heavy smoking 
reduces survival benefit in HPV+ OPSCC 
patients. This was reflected in our prog-
nostic model, developed using a “train-
ing” cohort from one center, where the 
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although human papillomavirus (hPV)+ oropharyngeal cancers often present with metastasis, most patients have 
excellent long-term survival. The reason underlying such an apparent contradiction remains unclear, but we have recently 
demonstrated that the improved survival of hPV+ oropharyngeal cancer patients has an immunological component, as 
the levels of tumor-infiltrating lymphocytes (TILs) can be used to stratify hPV+ patients into high-risk and low-risk groups.
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combination of TIL levels, heavy smok-
ing, and T-stage resulted in a statistically 
significant prediction (area under the 
ROC curve, AUROC = 0.87). This model 
was validated on patients from the other 
centers (detection rate = 67%; false-posi-
tive rate = 5.6%; AUROC = 0.82).
Our findings suggest that the 
improved survival of most HPV+ OPSCC 
patients results from an antitumor 
immune response, indicated by the pres-
ence of TIL. HPV preferentially targets 
the reticulated epithelium that lines ton-
sillar crypts, and it could be argued that 
the abundant lymphocytic infiltrate seen 
in most HPV+ OPSCCs simply reflects 
the anatomical location of the tumor. 
However, our analysis of a publically 
available head and neck squamous cell 
carcinoma (HNSCC) microarray data 
set revealed enrichment of genes associ-
ated with CD8+ T-cell effector functions 
in patients with improved survival, argu-
ing that the T cells are not simply “inno-
cent bystanders’’ of the biological events 
in the tumor, but play an active role in 
tumor recognition. HPV-16-specific 
T cells have been isolated from HPV+ 
OPSCCs,5 and E6/E7 seropositivity has 
been reported to be a favorable prognos-
tic factor in HPV+ OPSCC patients.6 The 
impact of the immune system may also 
explain why improved patient survival is 
seen independent of treatment modality 
in several studies, including our own.
If most HPV+ OPSCC are recognized by 
the immune system, the question is raised 
as to how tumors develop in the first place. 
The HPV proteins E5 and E7 have been 
reported to downregulate expression of 
MHC class I on the cell surface,7,8 thereby 
limiting antigen recognition by CD8+ 
Figure 1. Disease-specific survival of oropharyngeal squamous cell carcinoma (OPsCC) patients from independent cohorts. (A) Kaplan–Meier curves 
depicting the disease-specific survival of OPsCC patients stratified according to human papillomavirus (hPV) status (P < 0.001, P = 0.002, respectively, 
as per log rank test). (B) Kaplan–Meier curves depicting the disease-specific survival of OPsCC patients stratified according to hPV status and tumor-
infiltrating lymphocyte (TIL) levels. The survival of patients with hPV+/TILlow tumors is similar to that of hPV− patients. (C) hematoxylin and eosin (h+e)-
stained sections showing examples of OPsCC with high and low TIL levels. Tumor islands are marked with an asterix. In TILhigh OPsCCs, lymphocytes 
fill the stromal compartment and infiltrate into tumor islands. (D) Immunochemistry showing typical examples of hPV+ OPsCCs with high and low 
infiltrates of CD3+ T cells.
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T cells. In addition, several studies have 
shown that a degree of immunological tol-
erance may exist within the tonsils, which 
contain Foxp3+CD8+ T lymphocytes with 
a regulatory T cell (Treg) phenotype, as 
well as lymphocytes expressing CD28 fam-
ily members, cytotoxic T lymphocyte-asso-
ciated protein 4 (CTLA4), inducible T-cell 
co-stimulator (ICOS) and programmed 
cell death protein 1 (PDCD1, best known 
as PD-1).9,10 We can speculate that sur-
gery- or chemoradiotherapy-induced 
inflammation promotes the interferon γ 
(IFNγ)-dependent upregulation of MHC 
class I molecules or disrupts the immuno-
suppressive environment of OPSCC lesions 
in favor of an immunostimulatory one.
There is much interest in de-inten-
sifying the treatment of HPV+ OPSCC 
patients, in particular for avoiding the 
morbidity associated with standard che-
motherapeutic regimens. Our data sug-
gest that most of these patients have a 
pre-existing (albeit ineffective) antitumor 
immune response. Thus, the administra-
tion of antibodies targeting molecules 
involved in the co-stimulation or co-inhi-
bition of T cells including CTLA4, PD-1, 
PD-L1 and CD40, perhaps combined 
with a therapeutic anti-HPV-16 vaccine, 
may provide a useful therapeutic strat-
egy for patients with HPV+ OPSCCs. It 
will be interesting to determine whether 
an effective immune response can be 
generated by this approach in TILlow 
OPSCC patients. However, evaluation of 
TIL levels is an effective tool for identify-
ing the HPV+ OPSCC patients who are 
likely to respond poorly to conventional 
treatments, making it highly relevant for 
clinical decision making.
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